Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Melanoma treatment details. Immunotherapy. Sunnybrook Health Sciences Centre, Toronto, Canada

Survival: 12.4 months
Toxicity Grade: 4
Treatments: Immunotherapy
Country: Canada
City/State/Province: Toronto
Hospital: Sunnybrook Health Sciences Centre
Journal: Link
Date: 9/2012

This phase 2 study involved 40 metastatic melanoma patients who were not previously treated. The median patient age was 56 years and 24 patients were male.

Patients were treated with the immunotherapy agent interleukin 21 (IL-21), which is a cytokine that stimulates the immune system to attack cancer cells.

The most severe adverse events were grade 4 neutropenia and increased liver enzymes. Grade 3 rash was also reported.

The median overall survival was 12.4 months. The median progression-free survival was 4.3 months.

This study was partially supported by ZymoGenetics, which is part of the pharmaceutical company Bristol-Myers Squibb.

Correspondence: Dr. Teresa Petrella; email:

E-mail to a Friend Email Physician More Information